Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on October 1, 2018, and October 2, 2018, for Jaguar Health, Inc., a Delaware corporation. The filing details a material definitive agreement regarding debt obligations and the completion of an underwritten public offering of equity securities.
Key Financial Metrics and Transactions
- Debt Standstill Agreement: Entered into a Standstill Agreement with Chicago Venture Partners, L.P. (CVP) regarding outstanding secured promissory notes. CVP agreed to limit monthly redemptions to $500,000 until November 1, 2018.
- Standstill Fee: The Company agreed to pay CVP a fee equal to 5% of the total outstanding balance of CVP Notes as of November 1, 2018. This fee will be added to the principal balance of the oldest outstanding note.
- Equity Offering: On October 2, 2018, the Company priced an offering of 11,575,001 shares of Common Stock at $0.60 per share and 3,425,000 Pre-Funded Warrants at $0.59 per share.
- Proceeds: The offering generated total gross proceeds of approximately $9 million before fees and expenses. The offering closed on October 4, 2018.
- Over-Allotment: Underwriters were granted a 30-day option to purchase up to an additional 2,250,000 shares of Common Stock.
Material Changes and Conditions
The filing introduces a conditional extension of the debt standstill. If the Company redeems at least $1.5 million of the CVP Notes by October 31, 2018, CVP will extend the standstill on remaining notes until March 2019. Conversely, if the Company fails to consummate this proposed redemption by the deadline, CVP gains the right to redeem up to $1 million of the notes at any time thereafter, in addition to resuming its standard monthly redemption rights.
Outlook, Management Commentary, and Risks
Use of Proceeds: Management intends to use net proceeds from the equity offering to fund approximately $1.2 million to $1.6 million for non-clinical pipeline and business development activities. The remainder will support the commercialization of Mytesi and general working capital needs.
Risks and Contingencies: The Company faces liquidity pressure regarding the CVP Notes. Failure to meet the $1.5 million redemption target by October 31, 2018, triggers an immediate acceleration of redemption rights by the lender, potentially impacting cash flow and liquidity.
Investor Verification Checklist
- Verify the total outstanding balance of CVP Notes as of November 1, 2018, to calculate the exact 5% Standstill Fee liability.
- Confirm whether the Company successfully redeemed at least $1.5 million of CVP Notes by the October 31, 2018, deadline to secure the extended standstill.
- Review the final prospectus (File No. 333-227292) for details on underwriting discounts and the final net proceeds received.
- Monitor the exercise of the 30-day over-allotment option by the underwriters.